Award
NIH Reporter #1P50CA310825-01
Developing Novel Combination Immunotherapeutics for Non–Muscle-Invasive Bladder Cancer
Recipient
SLOAN-KETTERING INST CAN RESEARCH
Award Amount
$514,639.00
Ceiling
$514,639.00
Awarded
September 17, 2026
Identifier
1P50CA310825-01
National Cancer Institute funding supports research into combination immunotherapies for non–muscle-invasive bladder cancer, including investigation of the engineered anti-CD40 antibody 2141-V11 and its effects on dendritic cells and antitumor immunity.
Description
The project aims to elucidate how dendritic cells mediate immune responses to CD40 agonism, BCG, and other immunotherapies, and to inform combination treatment strategies for non–muscle-invasive bladder cancer. The work includes studying dendritic-cell and CD8 T-cell responses, testing combination approaches in preclinical models, and evaluating 2141-V11 alone and in combinations in patients.